Home > Insider Trading > Filing (0001209191-19-041112)

Filing Details

Accession Number:: 0001209191-19-041112
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-07-03 16:28:36
Reporting Period:: 2019-07-01

Accepted Time:: 2019-07-03 16:28:36
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1169245	Phasebio Pharmaceuticals Inc	PHAS	Pharmaceutical Preparations (2834)	030375697

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1592380	Clay Thorp	C/O Phasebio Pharmaceuticals, Inc. 1 Great Valley Parkway, Suite 30 Malvern PA 19355		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2019-07-01	2,014	$14.00	1,818,638	No	4	S	Indirect	By Hatteras Venture Partners III, LP
Common Stock	Disposition	2019-07-01	180	$14.00	162,890	No	4	S	Indirect	By Hatteras Venture Affiliates III, LP
Common Stock	Disposition	2019-07-01	255	$14.00	52,397	No	4	S	Indirect	By Hatteras Venture Partners I, LP
Common Stock	Disposition	2019-07-01	459	$14.00	415,959	No	4	S	Indirect	By Venture Capital Multiplier Fund

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By Hatteras Venture Partners III, LP
No	4	S	Indirect	By Hatteras Venture Affiliates III, LP
No	4	S	Indirect	By Hatteras Venture Partners I, LP
No	4	S	Indirect	By Venture Capital Multiplier Fund

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by HVP III, HV Affiliates, HVP I and Multiplier Fund (each as defined in Footnotes (4), (5) and (6) below).
The price reported in column 4 is a weighted average price. These shares were sold on multiple transactions at prices ranging from $14.00 to $14.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Amount has been adjusted to correct a de minimis clerical error in previous filings.
Hatteras Venture Advisors III, LLC ("HVA III") is the general partner of Hatteras Venture Partners III, LP ("HVP III") and Hatteras Venture Affiliates III, LP ("HV Affiliates"). The securities held directly by HVP III and HV Affiliates are indirectly held by HVA III. The reporting person is a manager of HVA III and may be deemed to share voting and dispositive power with regard to the securities directly held by HVP III, HV Affiliates and Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by HVP III and HV Affiliates except to the extent of his pecuniary interest therein.
Catalysta Ventures, LLC ("Catalysta") is the general partner of Hatteras Venture Partners I, LP ("HVP I"). The securities held directly by HVP I are indirectly held by Catalysta. The reporting person is a manager of Catalysta and may be deemed to share voting and dispositive power with regard to the securities held directly by Catalysta and HVP I. The reporting person disclaims beneficial ownership of the securities held by Catalysta and HVP I except to the extent of his pecuniary interest therein.
Hatteras Venture Advisors V, LLC ("HVA V") is the general partner of Venture Capital Multiplier Fund ("Multiplier Fund"). The securities held directly by Multiplier Fund are indirectly held by HVA V. The reporting person is a manager of HVA V and may be deemed to share voting and dispositive power with regard to the securities held by Multiplier Fund. The reporting person disclaims beneficial ownership of the securities held by Multiplier Fund except to the extent of his pecuniary interest therein.